Nav: Home

Study: Protein found to be key component in irregularly excited brain cells

July 17, 2018

CHAMPAIGN, Ill. -- In a new study in mice, researchers have identified a key protein involved in the irregular brain cell activity seen in autism spectrum disorders and epilepsy. The protein, p53, is well-known in cancer biology as a tumor suppressor.

The findings, reported in the journal Human Molecular Genetics, will open new avenues for understanding the factors that contribute to these developmental disabilities, said Nien-Pei Tsai, a University of Illinois professor of molecular and integrative physiology who led the new research.

"Under physiologically normal circumstances, neurons are able to readjust their excitability: the strength at which neurons are firing," Tsai said. "But in autism spectrum disorders, such as Fragile X syndrome, and in epilepsy, you see higher levels of excitability. Our brains need a baseline for neurons to return to after higher or lower neuron excitability. If the neurons can't return to a normal range, then the baseline is reset outside of a normal range."

This affects both behavioral characteristics and cognitive functioning, he said.

Using a mouse model of Fragile X syndrome, the most common inherited autism disorder, the researchers discovered a molecular mechanism involved in the inability to regulate excitability. The protein p53 is present in higher-than-normal levels in irregularly excitable neurons.

In an earlier study, Tsai found that p53 in neurons breaks down when normal neurons are at a higher excitable state. Previously, the protein was best known for its role in cancer suppression.

"Many patients with cancer have lower levels of p53 or mutated p53, and we know that this protein is important for cell division," Tsai said. "But the protein also is present in neurons, which do not divide, so we were interested in understanding the role the protein plays when it is not involved in cell division."

In the new study, researchers found that p53, which doesn't break down normally in Fragile X neurons, triggered a cascade of reactions that interfered with the normal signal to return to a calmer state, Tsai said.

"We don't yet know all the parts of this cascade, but we did find that p53 interferes with another important protein, Nedd4-2, that is associated with epilepsy," he said.

The researchers tested the cellular effect of reducing the protein by knocking down the p53 gene in their mouse model. They also inhibited the protein in neurons grown in cell culture with a drug used in cancer research to see the effect in communications between groups of neurons and one-to-one synaptic connections.

"We found that in both cases - removal of the p53 protein and inhibition of the protein - the connections between synapses and groups of neurons were able to return to a normal, stable state," Tsai said. "These findings show a previously unknown, and very strong, role that p53 is playing in irregular brain cell function."
-end-
The National Institutes of Health, the Brain and Behavioral Research Foundation and the Simons Foundation supported this research

Editor's notes:

To reach Nien-Pei Tsai, call 217-244-5620; email nptsai@illinois.edu.

The papers "Loss of fragile X protein FMRP impairs homeostatic synaptic downscaling through tumor suppressor p53 and ubiquitin E3 ligase Nedd4-2" and "Dysregulation and restoration of homeostatic network plasticity in fragile X syndrome mice" are available online and from the U. of I. News Bureau.

DOI: 10.1093/hmg/ddy189

DOI: 10.1016/j.neuropharm.2018.06.011

University of Illinois at Urbana-Champaign

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.